The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Open accessAbstract
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer’s disease (AD). Blood biomarkers can accurately detect AD pathology, but it is unclear whether their incorporation into a full diagnostic workflow can reduce the number of confirmatory cerebrospinal fluid (CSF) or positron emission tomography (PET) tests needed while accurately classifying patients. We evaluated a two-step workflow for determining Aβ-PET status in patients with mild cognitive impairment (MCI) from two independent memory clinic-based cohorts (n = 348). A blood-based model including plasma tau protein 217 (p-tau217), age and APOE ε4 status was developed in BioFINDER-1 (area under the curve (AUC) = 89.3%) and validated in BioFINDER-2 (AUC = 94.3%). In step 1, the blood-based model was used to stratify the patients into low, intermediate or high risk of Aβ-PET positivity. In step 2, we assumed referral only of intermediate-risk patients to CSF Aβ42/Aβ40 testing, whereas step 1 alone determined Aβ-status for low- and high-risk groups. Depending on whether lenient, moderate or stringent thresholds were used in step 1, the two-step workflow overall accuracy for detecting Aβ-PET status was 88.2%, 90.5% and 92.0%, respectively, while reducing the number of necessary CSF tests by 85.9%, 72.7% and 61.2%, respectively. In secondary analyses, an adapted version of the BioFINDER-1 model led to successful validation of the two-step workflow with a different plasma p-tau217 immunoassay in patients with cognitive impairment from the TRIAD cohort (n = 84). In conclusion, using a plasma p-tau217-based model for risk stratification of patients with MCI can substantially reduce the need for confirmatory testing while accurately classifying patients, offering a cost-effective strategy to detect AD in memory clinic settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A 3-range approach demonstrated high negative and positive concordance with Aβ status, with approximately 20% of individuals in an intermediate zone that would require confirmatory CSF or PET, as previously proposed.41”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, recent evidence suggests that a three-range method leads to higher accuracy to identify amyloid PET positivity in individuals with MCI56.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We next applied a 3-range approach,41 creating lower (95% sensitivity, <0.4 pg/mL) and upper (95% specificity, >0.63 pg/mL) reference points in WRAP (Table 2 and eFigure 11 in Supplement 1).”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the two-cutoffs approach is currently employed for the FDA-approved CSF Lumipulse test42,43 and has been suggested for AD BBMs17,55, especially when very high accuracy is needed.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationHarrell (2015) · Springer Series in Statistics · doi:10.1007/978-3-319-19425-7 · Cited by 6,878
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678 · cited 2×
“The inclusion criteria for recruitment of patients with MCI for BioFINDER-2 were as follows: (1) aged 40–100 years; (2) referred to the memory clinics due to cognitive symptoms; (3) MMSE score of 24–30 points; (4) did not fulfill the criteria for any dementia (major neurocognitive disorder) according to the Diagnostic…”
MethodNichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders
Bell, C. C. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520100096046 · Cited by 2,610
Levey, A. S., de Jong, P. E., Coresh, J., El Nahas, M., Astor, B. C., Matsushita, K., Gansevoort, R. T., Kasiske, B. L., & Eckardt, K.-U. (2011) · Kidney International · doi:10.1038/ki.2010.483 · Cited by 2,345
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationDiagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Notably, the two-cutoffs approach is currently employed for the FDA-approved CSF Lumipulse test 42,43 and has been suggested for AD BBMs 17,55 , especially when very high accuracy is needed.”
MethodSelf-citation
Metadata
- Authors
- Brum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., Servaes, S., Triana-Baltzer, G., Kolb, H. C., Palmqvist, S., Stomrud, E., Rosa-Neto, P., Blennow, K., & Hansson, O.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Lund University (SE)
- King's College London (GB)
- McGill University Research Centre for Studies in Aging (CA)
- Janssen Research & Development (United States) (US)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Brum, Wagner S.
- Hansson, Oskar
- ORCID
- Venue
- Nature Aging
- Published
- 2023-08-31
- Volume
- 3
- Issue
- 9
- Pages
- 1079-1090
- ISSN
- 2662-8465 (ISSN-L)
- PMC
- PMC10501903
- OpenAlex
- W4386324919
- Cited by
- 248
- References
- 65
- Citations by year
- 2026: 68 · 2025: 98 · 2024: 74 · 2023: 8
- FWCI
- 50.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Aging (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Alzheimer's Association (ZEN-21-848495, MOP-11-51-31, 159815, 2021 Zenith Award, NIRP-12-259245, RFN 152985, #NIRG‐12‐92090, 34874, 33397, 162303)
- Cure Alzheimer's Fund
- Fondation Brain Canada (ZEN-21-848495, 2020-VICO-279314, 34874, 33397)
- Stiftelsen för Gamla Tjänarinnor
- Weston Brain Institute (MOP-11-51-31, NIRP‐12‐259245)
- Australian Government (2022-Projekt0080)
- Consortium canadien en neurodégénérescence associée au vieillissement (MOP-11-51-31)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (MOP-11-51-31, 88887.596742/2020-00, 88887, NIRP-12-259245, RFN 152985, 159815, 2020-00, 162303, NIRG-12-92090)
- Lunds Universitet (AF-980907)
- Hjärnfonden (ALZ2022-0006), FO2021-0293, FO2017‑0243, FO2017, ZEN-21-848495, ALFGBG-715986, #ALFGBG-965240, 1412/22)
- Knut och Alice Wallenbergs Stiftelse (2017‐0383, 2022-Projekt0080, 2022-00775, AF-980907, 2022-1259, FO2021-0293, 2020-O000028, 1412/22)
- Vetenskapsrådet (ALFGBG-965240, ALZ2022-0006, ERAPERMED2021-184, 2017-00915, (#ALFGBG-715986, 2022-00775, ZEN-21-848495, 2022-Projekt0080, FO2021-0293, AF-980907, 1412/22, 2020-O000028, 2017-00383, FO2017-0243, 2022-1259)
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028, FO2017-0243)
- Skånes universitetssjukhus (2022-1259, 2020-O000028, 2022-Projekt0080)
- Parkinsonfonden (1412/22)
- Canadian Institutes of Health Research (#MOP-11-51-31, 33397, NIRP-12-259245, NIRG-12-92090, 152985, 159815, RFN 152,985, 162303, 92090)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- plasma p-tau217, Alzheimer's disease, mild cognitive impairment, blood biomarkers, risk stratification, APOE ε4, cost-effective diagnosis, memory clinics
- MeSH terms
- Alzheimer Disease, Blood Proteins, Humans, Tomography, X-Ray Computed, Amyloid beta-Peptides, Workflow
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. https://app.cochat.ai/papers/10.1038/s43587-023-00471-5
- The paper
- Brum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., Servaes, S., Triana-Baltzer, G., Kolb, H. C., Palmqvist, S., Stomrud, E., Rosa-Neto, P., Blennow, K., & Hansson, O. (2023). A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. Nature Aging. https://doi.org/10.1038/s43587-023-00471-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.